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ABSTRACT The Raf-1 protein kinase is the best-
characterized downstream effector of activated Ras. Interac-
tion with Ras leads to Raf-1 activation and results in trans-
duction of cell growth and differentiation signals. The details
of Raf-1 activation are unclear, but our characterization of a
second Ras-binding site in the cysteine-rich domain (CRD)
and the involvement of both Ras-binding sites in effective
Raf-l-mediated transformation provides insight into the mo-
lecular aspects and consequences ofRas-Raf interactions. The
Raf-1 CRD is a member of an emerging family of domains,
many of which are found within signal transducing proteins.
Several contain binding sites for diacylglycerol (or phorbol
esters) and phosphatidylserine and are believed to play a role
in membrane translocation and enzyme activation. The CRD
from Raf-1 does not bind diacylglycerol but interacts with Ras
and phosphatidylserine. To investigate the ligand-binding
specificities associated with CRDs, we have determined the
solution structure of the Raf-1 CRD using heteronuclear
multidimensional NMR. We show that there are differences
between this structure and the structures of two related
domains from protein kinase C (PKC). The differences are
confined to regions of the CRDs involved in binding phorbol
ester in the PKC domains. Since phosphatidylserine is a
common ligand, we expect its binding site to be located in
regions where the structures of the Raf-1 and PKC domains
are similar. The structure of the Raf-1 CRD represents an
example of this family of domains that does not bind diacyl-
glycerol and provides a framework for investigating its inter-
actions with other molecules.
Raf-1 is a serine/threonine kinase whose activation is regu-
lated by the action of extracellular signals such as hormones
and mitogens (1). A critical step in the activation of Raf-1 is
its interaction with membrane-anchored Ras, an oncoprotein
found to be deregulated in many human tumors (reviewed in
ref. 2). The activation of the Raf-1 kinase initiates the mitogen-
activated protein kinase cascade, which transduces cellular
growth and differentiation signals to the nucleus (3, 4). It has
been shown that Ras-mediated translocation of Raf-1 to the
plasma membrane is the first step of Raf activation, but Ras
interaction alone is not sufficient to activate the Raf-1 kinase
and other events, such as Raf-1 phosphorylation, may be
required (5, 6).
Raf proteins contain several conserved regions (reviewed in
ref. 1). At the carboxyl (C)-terminal end is the catalytic kinase
domain that shows specificity for phosphorylation of serine
and threonine residues. The amino (N)-terminal region of
Raf-1 is thought to be involved in negative regulation of the
kinase domain, since its removal or mutation can lead to
tumorigenesis (7-9). Residues 55-131, in the N terminus of
Raf-1, have been shown to constitute a Ras binding site (10,
11), termed Ras-binding site I (RBS-1). The structure of this
domain and the identification of the Ras-interaction surface
have recently been elucidated by nuclear magnetic resonance
(NMR) (12), and the structure of RBS-1 in a complex with the
Ras-related protein RaplA has also been solved by x-ray
crystallography (13). In addition, it has been shown that there
is a second, distinct, binding site for Ras (RBS-2) within the
conserved cysteine-rich domain (CRD) in the N-terminal
region of Raf-1 (14, 15). This CRD encompasses residues
139-184. Results from our laboratory (16) suggest that inter-
actions between Ras and both of these binding sites may be
required for Raf-mediated transformation. Studies with full-
length and truncated Raf-1 proteins, as well as various Ras
mutants, have suggested that these two binding sites interact
with distinct regions of Ras (16, 17), and that the RBS-2 may
be cryptic in intact, unstimulated Raf-1 (18). The Raf-1 CRD
has also been shown to be responsible for binding phospho-
lipids (14) and possibly 14-3-3 proteins (19-24). The role of
these interactions in Raf-1 activation is still unclear, although
a plethora of data suggests that the CRD may be involved (25,
26).
There is no structural information available on Raf-1 resi-
dues 139-184. Sequence comparisons show that this domain is
homologous to a family of CRDs (14), each of which bind two
molecules of zinc. These CRDs are found in several other
proteins involved in signal transduction such as protein kinase
C (PKC) (27), N-chimaerin (28), diacylglycerol kinase (29),
and Vav (30). In many of these proteins the CRD includes a
binding site for diacylglycerol (DAG) and tumor-promoting
phorbol esters (31), suggesting it may interact with the cell
membrane. The association with lipid bilayers is further im-
plicated by the demonstration that these CRDs also include
binding sites for phosphatidylserine (PS). It is notable that the
Raf-1 CRD does not bind DAG, even though it interacts with
PS (14).
The structures of homologous CRDs from PKC a and 6,
both of which bind DAG and phorbol esters, have recently
been solved and shown to consist of two small (3-sheets with a
very short helix at the C terminus (32, 33). To investigate
further the role of the CRD in Raf-1 activation, and the basis
of the ligand specificities in this family of domains, we have
determined its solution structure using two-dimensional (2D)
and three-dimensional (3D) heteronuclear NMR methods.
Here, we compare the structure of the Raf-1 CRD with the
structures of the CRDs from PKC. We show that, although the
overall topology of the molecules is similar, the second loop
Abbreviations: COSY, correlation spectroscopy; CRD, cysteine-rich
domain; 2D and 3D, two- and three-dimensional; DAG, diacylglycerol;
NOE, nuclear Overhauser enhancement; NOESY, NOE spectroscopy;
PKC, protein kinase C; PS, phosphatidylserine; RMSD, root mean
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that is implicated in DAG and phorbol ester binding in the
PKC domains has a very different structure in the Raf-1
domain. We suggest that these structural differences may
account for the different binding specificities of these domains.
MATERIALS AND METHODS
Expression and Purification. Residues 136-187 from Raf-1
were expressed in Escherichia coli and purified as described
(14). Pure protein in 30 mM Tris-acetate, pH 6.2/75 mM
Na2SO4/10 ,tM ZnCl2/1 mM DTT was concentrated to 1 ml
using an Amicon ultrafiltration stirred cell, containing a YM-1
membrane (Amicon) then exchanged into NMR buffer (30
mM dl,-Tris-d3-acetate, pH 6.2/75 mM Na2SO4/10 ,uM
ZnCl2/1 mM djo-DTT/10% D20/0.01% NaN3) using a Phar-
macia PD-10 gel filtration column. Finally, samples were
concentrated in a Centricon-3 (Amicon) to a final concentra-
tion of 0.5-1.0 mM in a volume of 550 ,ul. '5N-labeled protein
was obtained by growing E. coli with 99.8% 15NH4Cl as the sole
nitrogen source. D20 (2H20) samples were obtained by ex-
changing the protein twice, using the Pharmacia PD-10 col-
umn, into NMR buffer that had been made up with 99.9%
D20.
NMR Spectroscopy. NMR experiments were recorded at
25°C on a Bruker (Billerica, MA) AMX500 spectrometer. A
3D 15N-edited nuclear Overhauser enhancement (NOE) spec-
troscopy (NOESY) experiment (34) was recorded with sensi-
tivity-enhanced coherence order selection using pulsed-field
gradients (35), with a mixing time of 200 msec. A 3D 15N-
edited total correlation spectroscopy (TOCSY) experiment
(36) was recorded utilizing DIPSI-3 (37) with a mixing time of
70 msec. Three-dimensional experiments were acquired as
512 x 96 x 48 complex points, with spectral widths of 6024.1,
1250.0, and 6024.1 Hz for the fl, f2, and f3 dimensions,
respectively. Water suppression in the 3D TOCSY was
achieved using Watergate (38) and purging gradients. Two-
dimensional experiments were recorded on a sample in D20
as follows: double quantum filtered correlation spectroscopy
(DQF-COSY) (39), homonuclear TOCSY (40) with a 72 msec
DIPSI-3 mixing time, NOESY experiments (41) with mixing
times of 100 msec, 150 msec, and 200 msec. In these experi-
ments the residual water was suppressed using low power
saturation. The D20 experiments were typically acquired as
1024 x 512 complex points (except the COSY experiments,
which were recorded as 2048 x 512 complex points), with
spectral widths of 6024.1 Hz in each dimension. NH-CaH
coupling constants were identified from a series of 2D 'H-15N
J-modulated COSY experiments (42), where the NH-CaH
J-coupling was allowed to evolve for 10-110 msec, incremented
in 10 msec steps in each successive experiment. The J-
couplings were evaluated by fitting the cross-peak intensities as
previously described (42), using a program provided by F. Moy.
CaH-CPH coupling constants were identified from a primitive
exclusive COSY experiment (43) and these were used to
estimate XI angles in combination with NOESY experiments
recorded with mixing times of 60 msec. Hydrogen bonds were
identified by the presence of slowly exchanging amide protons
in a 2D 'H NOESY experiment that was recorded -20 hr after
the sample was buffer-exchanged into D2O. NMR data were
processed and analyzed using the program FELIX, version 2.30
(Biosym Technologies, San Diego). In the 3D experiments,
linear prediction was used in the indirect dimensions to double
the number of complex points.
Structure Calculation. Structure calculations were per-
formed using X-PLOR, version 3.1 (44), following the hybrid
distance-geometry/simulated annealing protocol as described
in the X-PLOR manual except that the high temperature
dynamics was increased in length to 32 psec. A total of 602
NMR-derived restraints were used, including 553 NOE re-
straints, of which 119 were sequential, 41 were short-range
(2-4 residues apart in sequence), and 141 were long-range (5
or more residues apart in the sequence). There were five pairs
of hydrogen bonds identified from slowly exchanging amide
protons, where the carbonyl donors were identified by exam-
ination of the initial structures that had been calculated on the
basis ofNOEs only. In addition, 28 4 restraints were identified
from the J-modulated COSY experiment, where a coupling
constant of >8 Hz was associated with a 4 angle of -139° ±
30, and a coupling constant of <6 Hz was associated with a 4)
angle of -60° ± 30. There were also 11 XI restraints measured
from a combination of PE-COSY and 60 msec NOESY
experiments recorded in H20 and D20. The structure calcu-
lations were initially run with no Zn2+ restraints, and the
identity of the Zn2+ binding residues could be inferred from
their positions, as well as the homology to the CRDs from
PKC. The histidine ring nitrogen involved in coordinating
Zn2+ was identified by recording a 15N-'H heteronuclear single
quantum correlation spectrum with a total 'H-'5N evolution
period of 22 msec, and the 15N spectral frequency shifted by
+5000 Hz relative to the regular 15N frequency (45). The
evolution period used ensured that direct 'H-15N couplings
were minimized, and only the multi-bond couplings in the
histidine ring were observed. The Zn2+ was then added and
held in place by NOE distances of 2.3 A for S-Zn2+ and 2.0 A
for N-Zn2+ (46).
RESULTS AND DISCUSSION
Secondary Structure and Topology. The 2D and 3D NMR
datasets collected on the Raf-1 CRD enabled almost complete
resonance assignment. The 3D 15N-edited TOCSY experiment
was used to correlate the backbone amide resonances with the
intra-residue CaH and side-chain proton resonances and the
3D '5N-edited NOESY spectrum was used to complete spin
system identification and establish sequential connectivities.
The spin system assignments were then extended using the 2D
and 3D spectra (47). The residues whose resonances could not
be assigned included the three N-terminal amino acids (Raf-1
residues 136-138), which are outside the consensus sequence
for these domains, and the backbone amide protons of Leu-147
and Thr-178. Long-range NOEs were identified from both 2D
and 3D NOESY experiments.
The protonation of the histidine nitrogens was assessed
using the 15N-'H heteronuclear single quantum correlation as
described in Materials and Methods. It was evident from the
characteristic chemical shifts of the histidine nitrogen reso-
nances in this spectrum and the 2- and 3-bond coupling
constants within the histidine ring that the Ne2 was protonated
and the N11 was deprotonated under the sample conditions
(48). Thus it is likely that the N81 is the nitrogen involved in
coordinating with Zn2+, the same nitrogen as that observed in
PKC. These results suggest that this scheme of Zn2+ coordi-
nation may be conserved in all CRDs.
The secondary structure of the Raf-1 CRD could be as-
signed on the basis of short- and medium-range NOEs and
coupling constants, as summarized in Fig. 1. It is composed of
5 (3-strands, encompassing residues 140-146, 150-151, 157-
159, 161-165, and 170-173 and a region that has some helical
character, encompassing residues 177-180. The backbone
amide proton resonances of several residues within this helix
are broad, suggesting that they are involved in chemical
exchange. The helix is ill-defined by the short-range NOEs and
coupling constants, but it is clearly present in the 3D struc-
tures; thus it is defined by long-range interactions involving the
side-chains rather than the short-range interactions involving
the backbone amide protons.
The overall topology of this domain can be inferred from the
pattern of long-range NOEs as shown in Fig. 2 and from the
representation of the structure shown in Fig. 3A. Thus, there
are two (B-sheets: the first comprises the first, fourth, and fifth
Biochemistry: Mott et al.
Proc. Natl. Acad. Sci. USA 93 (1996)
nn(i+1)
an(i+1)
fon(i+1)
nn(i+2)
an(i+2)
Pin(i+2)
140 145 150 155 160 165 170 175 180 185
L T T H N FAR K T F LK LA F CD I C QK F L L N G FR COT CG Y K F HE H CS T K V PT MC V DW
m - ~ - m ~ - - - - -
ab(i+3)
Jhn-ha EEEOE.. -O- 0OOE- - ME E- O-E * 00- 0 U
FIG. 1. Summary of the short-range NOEs and coupling constants observed for the Raf-1 CRD. NOEs were classified into strong, medium,
and weak, and their strength is indicated by the width of the bar in each case. nn(i + 1) refers -to a NOE between the backbone NH of residue
i and the NH of residue i + 1. The other NOE types are represented in a similar way. Coupling constants of less than 6 Hz are represented by
open squares and those of greater than 8 Hz by filled squares. This figure was generated with a program provided by Bruno Kieffer (University
of Strasbourg).
13-strands and the second comprises the second and third
13-strands. The C-terminal helix packs against the first
13-strand, so that the N and C termini come together to form
one Zn2+ binding site. The second Zn2+ binding site is formed
from residues in the loop between the second and third
1-strands and the loop between the fifth 13-strand and the
C-terminal helix. The structures are in good agreement with
the experimental data, with no NOE violations more than 0.5
A and no dihedral angle violations more than 5°. The root
mean squared deviation (RMSD) over all backbone atoms
within the consensus sequence for this motif is 0.92 A. The
residues outside the consensus sequence, 136-138 and 185-
187, are disordered and are not included in the structural
statistics.
Several regions of the structure exhibit flexibility, as judged
from the RMSDs, and a decrease in the heteronuclear NOE
(data not shown). One such region is the C-terminal helix. It
appears that this helix is solvent-exposed with broad backbone
amide resonances that prevented heteronuclear NOE mea-
surements. These large linewidths also impeded the assign-
ment of NOEs involving the backbone atoms in this helix. The
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FIG. 2. Summary of all the NOEs assigned for the Raf-1 CRD in
the form of a scatter plot. Each square represents a single NOE. The
positions of the ,3-strands and a-helix are indicated.
lack of NOEs accounts for the high RMSD in this region, but
whether this is due to conformational exchange or a high
degree of solvent exposure is not clear. This mobility may be
due to the excision of this domain from the full-length Raf-1
protein, since the extreme C terminus of this construct,
residues 185-187, is disordered. Alternatively, since mobile
regions in proteins are often involved in interactions with other
molecules, the C-terminal helix of the Raf-1 CRD may be
involved in ligand interactions. One of the other regions of
flexibility encompasses residues 146-150, and the significance
these residues will be discussed below. The RMSD of the
backbone atoms decreases significantly, from 0.9 A to 0.4 A
when these two mobile regions are removed from the calcu-
lation, as shown in Table 1.
Comparison of Raf-1 CRD with CRDs from PKC Reveals
Structural and Dynamic Differences in a Ligand-Binding
Region. A comparison with the CRDs from PKC a determined
by NMR (32) methods and PKC 6 determined by x-ray
crystallography (33), shows that all three have a similar
secondary structure. The sequence alignments and position of
the secondary structural elements of all three domains are
shown in Fig. 4. This shows that the lengths of the secondary
structural elements are conserved between all three CRDs,
and thus are likely to be similar in other members of the family,
such as Vav and DAG kinase.
A combination of mutagenesis and structural work has
identified the position of residues in PKC 6 that interact with
phorbol ester (33, 51). Competitive binding and mutagenesis
data suggest that DAG and phorbol ester bind the same site in
PKC (reviewed in ref. 52). The position of these residues is also
identified in the sequence comparison, and it is apparent that
one of the two regions of the sequence involved in phorbol
ester binding to the PKC 6 CRD corresponds to a deletion in
the Raf-1 domain. Thus it is of interest to compare the 3D
structures of the Raf-1 and PKC 8 domains to determine the
differences in these ligand-binding regions.
Fig. 5 shows a comparison of the x-ray crystal structure of
the PKC 6 CRD, complexed with phorbol ester (33), with the
structure of the Raf-1 CRD. The first region of PKC 6 that
interacts with phorbol ester, the loop between 13-strands 1 and
2, is very similar in the two CRDs, even though the sequences
of the two domains are not conserved in this region. However,
the second region, the loop between 1B-strands 3 and 4 is the
position of this deletion in the Raf-1 domain. It is shorter than
the corresponding loop in the PKC domains and some of the
residues that interact with the phorbol ester in the PKC 6
domain are not present in the Raf-1 domain. These differences
in the structures of the second loop, combined with the lack of
8314 Biochemistry: Mott et al.
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FIG. 3. (A) A ribbon representation of a typical structure of the CRD, with the Zn2+ ions illustrated as black spheres. The side chains
corresponding to cysteine and histidine residues involved in Zn2+ coordination are also displayed. (B) A Co trace showing 16 representative final
structures, superimposed over all residues shown, in approximately the same orientation as in A. These figures were generated using MOLSCRIPT
(49).
sequence conservation in the first loop, are a likely explanation
for why the Raf-1 CRD does not bind to phorbol esters. The
deletion in this loop of the Raf-1 CRD introduces more
asymmetry in this region, so that the loop cannot form one side
of the binding pocket.
A consensus sequence within the CRD of Raf-1 has been
identified by sequence comparison of Raf and Ras-GTPase
activating protein family members (50). This sequence in
full-length Raf-1 is near the N terminus of the CRD, from
Arg-143 to Ala-150, and is highlighted in Fig. 4. Peptides
corresponding to this consensus sequence were found to
inhibit Raf-1 dependent phosphorylation of mitogen-activated
protein kinase (50). There is no direct evidence that this region
of the domain interacts with Ras, but these residues may be
involved in Raf-1 activation. Residues 146-150, within this
consensus sequence, appear to be more mobile than the other
loops, based on the convergence of the structures and the
dynamics measurements, as discussed above. Interestingly, the
corresponding loops in the PKC a NMR structure, that are
thought to interact with DAG and phorbol esters, appeared to
be less well-defined by the data. The binding of phorbol ester
to these two loops in the PKC 8 domain causes a shift in the
relative orientations of the loops and pushes them apart by
-0.4 A. The shift in the orientation of these loops would be
facilitated by their mobility. Since in the Raf-1 CRD only one
of these loops appears to be mobile, their relative orientation
cannot be changed in the same way as those in the homologous
domain from PKC 8. This may be an additional factor in why
Raf-1 cannot bind phorbol esters.
Implications for Interactions with Other Molecules. We
have presented the structure of a CRD family member that
does not bind DAG or phorbol esters. Knowledge of the
structure facilitates studies of the binding and interactions with
the activators of Raf-1. These studies will also form the basis
for elucidating how this small domain may simultaneously bind
several ligands, including Ras and PS. It is clear that there is
a dichotomy within this family of domains that divides them
into those that bind DAG and those that do not. We have
Table 1. Structural statistics for the 27 final structures of the
Raf-1 CRD
RMSDs from experimental restraints
All NOEs 0.045 (0.0052) A
Intraresidue NOEs (ij, j = 1) 0.043 (0.0009) A
Sequential NOEs (ij, j = i + 1) 0.018 (0.0050) A
Short-range NOEs (ij, i + 2 c j c i + 4) 0.052 (0.0247) A
Long-range NOEs (ij, j 2 i + 5) 0.054 (0.0091) A
Hydrogen bonds 0.085 (0.0161) A
Dihedral angles 0.335 (0.1096)0
Bonds
Angles
Impropers
RMSDs from ideal geometry
0.006 (0.0002) A
0.697 (0.050)°
0.614 (0.044)°
Energy
FNOE*
Ftort
Eli
33.46 (4.58) kcal mol-1
0.437 (0.21) kcal-mol-'
- 128.1 (6.44) kcal mol-
Atomic RMS differences
Residues 139-184:
Backbone atoms only
All heavy atoms
Residues 139-145 and 150-176:
Backbone atoms only
All heavy atoms
0.926 (0.231) A
1.374 (0.203) A
0.441 (0.123) A
1.024 (0.141) A
The numbers in parentheses are the standard deviations.
*Calculated with a force constant of 50 kcal.mol-LA-2.
tCalculated with a force constant of 200 kcal mol-l rad-1.
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Raf-1 HNFARKTFLKLAFCDICQKFLL .... NGFRCQTCGYKFHEHCSTKVPTMC
(139-184)
PKCa HKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLC
(102-151)
PKC6 HRFKVYNYMSPTFCDHCGTLLWGLVKQGLKCEDCGMNVHHKCREKVANLC
(231-280)
FIG. 4. The sequence alignment of the CRDs from Raf-1 and the PKC a and 8 forms. Shown above each sequence is the position of the secondary
structure, with the a-strands denoted by arrows and the a-helix by a shaded box. The shaded region in the Raf-1 sequence corresponds to the
consensus sequence thought to be involved in Raf-1 activation (50). The shaded regions in the PKC 8 sequence correspond to the residues implicated
in phorbol ester binding (33).
shown that the difference in specificity of the Raf-1 and PKC
domains may be accounted for by a difference in the structure
of one of the loops that is critical for the interaction between
PKC and its activator, phorbol ester.
The PKC domains are thought to bind phospholipid in a
manner that does not compete with the binding of DAG (53),
suggesting that the phospholipid binding site is distinct from
the phorbol ester/DAG binding site. The binding of phorbol
ester to the CRD of PKC 6 has been suggested to result in the
formation of a contiguous hydrophobic patch that may be
involved in plasma membrane insertion (33). This model for
membrane insertion is consistent with the hypothesis that this
CRD can bind both DAG and PS simultaneously, as both are
part of the lipid bilayer. Hence, the binding sites for these
activators may be on the same surface of the domain.
A
Membrane interactions are also involved in the activation of
the Raf-1 CRD, which binds the membrane-bound protein Ras
and also the phospholipid PS. The binding site for PS may
reside in regions of the structure that are conserved in both the
Raf-1 and PKC CRDs, since this is a common ligand. Based on
our model, the formation of a complex between Ras, PS, and
the N terminus of Raf-1 is necessary for activation of the Raf-1
kinase (14, 18). However, in this case, one of the activators
(H-Ras) is not inserted into the membrane like PS or DAG, but
rather is anchored to the membrane by a lipid moiety on the
C terminus. Thus the binding of Ras to the Raf-1 CRD is
unlikely to facilitate plasma membrane insertion, and the
relative orientation of the Ras/PS binding sites in the Raf-1
domain may be different to the orientation of the DAG/PS
binding sites in the PKC domains. The identification of these
,phorbol- 1 3-
acetate
FIG. 5. Comparison of the structures of (A) the Raf-1 CRD and (B) the PKC 8 CRD in a.complex with a phorbol ester (33), generated using
Molscript (49). One of the loops involved in interacting with phorbol ester in the PKC 8 CRD is truncated in the Raf-1 CRD.
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binding sites by both NMR and mutagenesis approaches is an
effort ongoing in our laboratory.
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